# Semax

> Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10), originally developed in Russia as a nootropic and neuroprotective research compound. It has been studied for cognitive support, attention, and recovery after ischemic brain injury, with decades of published research from Eastern Europe and more limited independent Western data. Semax lacks the hormonal, corticosteroid-stimulating activity of native ACTH while retaining central nervous system effects attributed largely to its proline-glycine-proline (PGP) fragment. It is classified as a research compound in most Western jurisdictions and is not approved by the FDA for any use. Available human evidence comes largely from small trials conducted outside the United States, so conclusions about efficacy and long-term safety remain preliminary and should not be treated as medical guidance.

- URL: https://www.lifeconverted.com/peptides/semax
- Primary category: Cognitive & Neuro
- Effectiveness rank: #2 in Cognitive & Neuro
- Evidence level: Well studied
- Route: Subcutaneous (Historically administered intranasally in Russian clinical and research use; this profile reflects subcutaneous injection as used in current research contexts.)
- Dose range: 200-600 mcg
- Dose tiers: low 200 mcg; moderate 400 mcg; high 600 mcg
- Half-life: Plasma half-life is very short, estimated at well under an hour due to rapid enzymatic degradation, though biologically active metabolites may prolong functional effects for several hours.
- Timing: Morning
- Cycle: 4-6 weeks on, 2-4 weeks off (Cycling is commonly discussed in research and vendor literature to limit theoretical tolerance, but no controlled human studies have established an optimal on/off schedule.)
- Storage: Store lyophilized peptide refrigerated (2-8°C) or frozen prior to reconstitution, protected from light. After reconstitution with bacteriostatic or sterile water, keep refrigerated and use within about 2-4 weeks.

## Mechanism of action

Semax is thought to act primarily by upregulating expression of brain-derived neurotrophic factor (BDNF) and modulating central dopaminergic and serotonergic signaling, which may support synaptic plasticity and attention-related circuits. Its PGP metabolite is proposed to carry much of the compound's neuroactive effect independent of the parent peptide. Some research also points to effects on cerebral blood flow and antioxidant activity in neural tissue. These mechanisms are drawn largely from animal and in vitro models, and their translation to humans is not fully established.

## Reported benefits

- Associated in research with improved attention and short-term memory performance
- Studied for potential neuroprotective effects following cerebral ischemia
- May support mood stability and reduced stress-related symptoms in some studies
- Explored for supporting cognitive recovery after brain injury
- Reported non-sedating profile compared with some classic nootropic agents

## Reported side effects

- Headache or irritability reported in some users
- Injection site irritation with subcutaneous administration
- Anxiety or overstimulation at higher doses in anecdotal reports
- Insufficient long-term human safety data to characterize rare risks

## Common protocols

- Short daily research courses of several weeks followed by a break
- Single daily dosing in the morning to align with reported alertness effects

## Stacking notes

Often discussed alongside Selank or Cerebrolysin in cognitive-focused research protocols; no controlled trials have evaluated these combinations for safety or added benefit.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer